Nantahala Capital Management
Latest statistics and disclosures from Nantahala Capital Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are XBI, XBI, IWM, IWM, SLNO, and represent 37.33% of Nantahala Capital Management's stock portfolio.
- Added to shares of these 10 stocks: XBI (+$211M), SLNO (+$99M), COST (+$46M), IWM (+$45M), EOLS (+$26M), RMBL (+$21M), ESTA (+$14M), Abivax SA F (+$11M), Tourmaline Bio (+$11M), VTGN (+$9.3M).
- Started 18 new stock positions in CLRB, Neurogene, AYX, CONN, Instil Bio, VTGN, NVNO, StarTek, GRPH, ZYXI. EAR, FBIO, Abivax SA F, Tourmaline Bio, CHEK, THTX, COST, Cutera.
- Reduced shares in these 10 stocks: , CASH (-$9.2M), Talaris Therapeutics (-$8.3M), RH (-$6.1M), CYTK (-$5.8M), IMTX (-$5.3M), VTYX (-$5.1M), KRTX (-$5.1M), GOSS, MLKN.
- Sold out of its positions in AAN, Acer Therapeutics, AKUMQ, TBBK, BXMT, CCCC, Catalyst Biosciences, ELTX, Fortress Biotech, Instil Bio. DERM, KRTX, Neoleukin Therapeutics, Nogin, Nogin, Point Biopharma Global, KRE, Talaris Therapeutics, TGTX, VTYX, ADCT, INMD.
- Nantahala Capital Management was a net buyer of stock by $463M.
- Nantahala Capital Management has $3.3B in assets under management (AUM), dropping by 185.60%.
- Central Index Key (CIK): 0001472322
Tip: Access up to 7 years of quarterly data
Positions held by Nantahala Capital Management consolidated in one spreadsheet with up to 7 years of data
Download as csv Download as ExcelPortfolio Holdings for Nantahala Capital Management
Nantahala Capital Management holds 231 positions in its portfolio as reported in the December 2023 quarterly 13F filing
Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
---|---|---|---|---|---|---|
Spdr Ser Tr S&p Biotech Put Option (XBI) | 8.9 | $296M | +248% | 3.3M | 89.29 |
|
Spdr Ser Tr S&p Biotech Put Option (XBI) | 8.9 | $296M | +248% | 3.3M | 89.29 |
|
Ishares Tr Russell 2000 Etf (IWM) | 8.1 | $271M | +20% | 1.3M | 200.71 |
|
Ishares Tr Russell 2000 Etf (IWM) | 8.1 | $271M | +20% | 1.3M | 200.71 |
|
Soleno Therapeutics (SLNO) | 3.4 | $115M | +627% | 2.9M | 40.25 |
|
Soleno Therapeutics (SLNO) | 3.4 | $115M | +627% | 2.9M | 40.25 |
|
Establishment Labs Holdings Ord (ESTA) | 2.3 | $78M | +22% | 3.0M | 25.89 |
|
Establishment Labs Holdings Ord (ESTA) | 2.3 | $78M | +22% | 3.0M | 25.89 |
|
Meta Financial (CASH) | 1.7 | $56M | -14% | 1.1M | 52.93 |
|
Meta Financial (CASH) | 1.7 | $56M | -14% | 1.1M | 52.93 |
|
Costco Wholesale Corporation Put Option (COST) | 1.4 | $46M | NEW | 70k | 660.08 |
|
Costco Wholesale Corporation Put Option (COST) | 1.4 | $46M | NEW | 70k | 660.08 |
|
Imax Corp Cad (IMAX) | 1.2 | $40M | -6% | 2.7M | 15.02 |
|
Imax Corp Cad (IMAX) | 1.2 | $40M | -6% | 2.7M | 15.02 |
|
Hilton Grand Vacations (HGV) | 1.1 | $37M | +22% | 921k | 40.18 |
|
Hilton Grand Vacations (HGV) | 1.1 | $37M | +22% | 921k | 40.18 |
|
Rumbleon Com Cl B (RMBL) | 1.1 | $36M | +144% | 4.4M | 8.14 |
|
Rumbleon Com Cl B (RMBL) | 1.1 | $36M | +144% | 4.4M | 8.14 |
|
Bioventus Com Cl A (BVS) | 0.9 | $32M | 6.0M | 5.27 |
|
|
Bioventus Com Cl A (BVS) | 0.9 | $32M | 6.0M | 5.27 |
|
|
Evolus (EOLS) | 0.9 | $31M | +591% | 2.9M | 10.53 |
|
Evolus (EOLS) | 0.9 | $31M | +591% | 2.9M | 10.53 |
|
Peloton Interactive Cl A Com (PTON) | 0.8 | $27M | 4.4M | 6.09 |
|
|
Peloton Interactive Cl A Com (PTON) | 0.8 | $27M | 4.4M | 6.09 |
|
|
Red Violet (RDVT) | 0.7 | $24M | -4% | 1.2M | 19.97 |
|
Red Violet (RDVT) | 0.7 | $24M | -4% | 1.2M | 19.97 |
|
America's Car-Mart (CRMT) | 0.7 | $24M | +35% | 312k | 75.77 |
|
America's Car-Mart (CRMT) | 0.7 | $24M | +35% | 312k | 75.77 |
|
Uniqure Nv SHS (QURE) | 0.6 | $21M | 3.2M | 6.77 |
|
|
Uniqure Nv SHS (QURE) | 0.6 | $21M | 3.2M | 6.77 |
|
|
Lyra Therapeutics (LYRA) | 0.6 | $21M | 4.1M | 5.24 |
|
|
Lyra Therapeutics (LYRA) | 0.6 | $21M | 4.1M | 5.24 |
|
|
Luxfer Hldgs SHS (LXFR) | 0.5 | $16M | -14% | 1.8M | 8.94 |
|
Luxfer Hldgs SHS (LXFR) | 0.5 | $16M | -14% | 1.8M | 8.94 |
|
Zevra Therapeutics Com New (ZVRA) | 0.5 | $16M | +6% | 2.5M | 6.55 |
|
Zevra Therapeutics Com New (ZVRA) | 0.5 | $16M | +6% | 2.5M | 6.55 |
|
Viemed Healthcare (VMD) | 0.5 | $15M | -3% | 2.0M | 7.85 |
|
Viemed Healthcare (VMD) | 0.5 | $15M | -3% | 2.0M | 7.85 |
|
Immatics SHS (IMTX) | 0.4 | $15M | -26% | 1.4M | 10.53 |
|
Immatics SHS (IMTX) | 0.4 | $15M | -26% | 1.4M | 10.53 |
|
Amneal Pharmaceuticals Com Stk Cl A (AMRX) | 0.4 | $14M | +5% | 2.3M | 6.07 |
|
Amneal Pharmaceuticals Com Stk Cl A (AMRX) | 0.4 | $14M | +5% | 2.3M | 6.07 |
|
Codexis (CDXS) | 0.4 | $14M | -9% | 4.6M | 3.05 |
|
Codexis (CDXS) | 0.4 | $14M | -9% | 4.6M | 3.05 |
|
Abeona Therapeutics Com New (ABEO) | 0.4 | $14M | +17% | 2.8M | 5.01 |
|
Abeona Therapeutics Com New (ABEO) | 0.4 | $14M | +17% | 2.8M | 5.01 |
|
Keros Therapeutics (KROS) | 0.4 | $13M | -5% | 322k | 39.76 |
|
Keros Therapeutics (KROS) | 0.4 | $13M | -5% | 322k | 39.76 |
|
Syndax Pharmaceuticals (SNDX) | 0.4 | $12M | +28% | 565k | 21.61 |
|
Syndax Pharmaceuticals (SNDX) | 0.4 | $12M | +28% | 565k | 21.61 |
|
Neuropace (NPCE) | 0.4 | $12M | -3% | 1.2M | 10.31 |
|
Neuropace (NPCE) | 0.4 | $12M | -3% | 1.2M | 10.31 |
|
Noodles & Co Com Cl A (NDLS) | 0.4 | $12M | +7% | 3.7M | 3.15 |
|
Noodles & Co Com Cl A (NDLS) | 0.4 | $12M | +7% | 3.7M | 3.15 |
|
Aura Biosciences (AURA) | 0.4 | $12M | +77% | 1.3M | 8.86 |
|
Aura Biosciences (AURA) | 0.4 | $12M | +77% | 1.3M | 8.86 |
|
Rh Call Option (RH) | 0.3 | $12M | -34% | 40k | 291.48 |
|
Rh Call Option (RH) | 0.3 | $12M | -34% | 40k | 291.48 |
|
Golden Entmt (GDEN) | 0.3 | $12M | -12% | 291k | 39.93 |
|
Golden Entmt (GDEN) | 0.3 | $12M | -12% | 291k | 39.93 |
|
Rmr Group Cl A (RMR) | 0.3 | $11M | -6% | 404k | 28.23 |
|
Rmr Group Cl A (RMR) | 0.3 | $11M | -6% | 404k | 28.23 |
|
Reservoir Media (RSVR) | 0.3 | $11M | +57% | 1.6M | 7.13 |
|
Reservoir Media (RSVR) | 0.3 | $11M | +57% | 1.6M | 7.13 |
|
eHealth (EHTH) | 0.3 | $11M | +23% | 1.2M | 8.72 |
|
eHealth (EHTH) | 0.3 | $11M | +23% | 1.2M | 8.72 |
|
Abivax Sa Sponsored Ads | 0.3 | $11M | NEW | 1.0M | 10.70 |
|
Abivax Sa Sponsored Ads | 0.3 | $11M | NEW | 1.0M | 10.70 |
|
Tourmaline Bio | 0.3 | $11M | NEW | 411k | 26.18 |
|
Tourmaline Bio | 0.3 | $11M | NEW | 411k | 26.18 |
|
Enova Intl (ENVA) | 0.3 | $10M | +239% | 181k | 55.36 |
|
Enova Intl (ENVA) | 0.3 | $10M | +239% | 181k | 55.36 |
|
Industrial Logistics Pptys T Com Shs Ben Int (ILPT) | 0.3 | $9.4M | -15% | 2.0M | 4.70 |
|
Industrial Logistics Pptys T Com Shs Ben Int (ILPT) | 0.3 | $9.4M | -15% | 2.0M | 4.70 |
|
Vistagen Therapeutics Ord (VTGN) | 0.3 | $9.3M | NEW | 1.8M | 5.14 |
|
Vistagen Therapeutics Ord (VTGN) | 0.3 | $9.3M | NEW | 1.8M | 5.14 |
|
Cytokinetics Com New (CYTK) | 0.3 | $9.2M | -38% | 110k | 83.49 |
|
Cytokinetics Com New (CYTK) | 0.3 | $9.2M | -38% | 110k | 83.49 |
|
Herbalife Com Shs Call Option (HLF) | 0.3 | $9.2M | 600k | 15.26 |
|
|
Herbalife Com Shs Call Option (HLF) | 0.3 | $9.2M | 600k | 15.26 |
|
|
Amylyx Pharmaceuticals (AMLX) | 0.3 | $9.1M | +52% | 620k | 14.72 |
|
Amylyx Pharmaceuticals (AMLX) | 0.3 | $9.1M | +52% | 620k | 14.72 |
|
Payoneer Global (PAYO) | 0.3 | $9.1M | +8% | 1.7M | 5.21 |
|
Payoneer Global (PAYO) | 0.3 | $9.1M | +8% | 1.7M | 5.21 |
|
Silverback Therapeutics (SPRY) | 0.3 | $8.7M | +45% | 1.6M | 5.48 |
|
Silverback Therapeutics (SPRY) | 0.3 | $8.7M | +45% | 1.6M | 5.48 |
|
Dyne Therapeutics (DYN) | 0.3 | $8.5M | -5% | 643k | 13.30 |
|
Dyne Therapeutics (DYN) | 0.3 | $8.5M | -5% | 643k | 13.30 |
|
Assertio Holdings Com New (ASRT) | 0.2 | $8.2M | +63% | 7.6M | 1.07 |
|
Assertio Holdings Com New (ASRT) | 0.2 | $8.2M | +63% | 7.6M | 1.07 |
|
Tarsus Pharmaceuticals (TARS) | 0.2 | $7.6M | +176% | 375k | 20.25 |
|
Tarsus Pharmaceuticals (TARS) | 0.2 | $7.6M | +176% | 375k | 20.25 |
|
Tela Bio (TELA) | 0.2 | $7.3M | +140% | 1.1M | 6.62 |
|
Tela Bio (TELA) | 0.2 | $7.3M | +140% | 1.1M | 6.62 |
|
Zoom Video Communications In Cl A Call Option (ZM) | 0.2 | $7.2M | 100k | 71.91 |
|
|
Zoom Video Communications In Cl A Call Option (ZM) | 0.2 | $7.2M | 100k | 71.91 |
|
|
Dhi (DHX) | 0.2 | $6.8M | -2% | 2.6M | 2.59 |
|
Dhi (DHX) | 0.2 | $6.8M | -2% | 2.6M | 2.59 |
|
Dxp Enterprises Com New (DXPE) | 0.2 | $6.8M | +12% | 202k | 33.70 |
|
Dxp Enterprises Com New (DXPE) | 0.2 | $6.8M | +12% | 202k | 33.70 |
|
Reading Intl Cl A (RDI) | 0.2 | $6.5M | +18% | 3.4M | 1.91 |
|
Reading Intl Cl A (RDI) | 0.2 | $6.5M | +18% | 3.4M | 1.91 |
|
Inspiremd (NSPR) | 0.2 | $5.8M | +16% | 2.1M | 2.81 |
|
Inspiremd (NSPR) | 0.2 | $5.8M | +16% | 2.1M | 2.81 |
|
NN (NNBR) | 0.2 | $5.6M | +3% | 1.4M | 4.00 |
|
NN (NNBR) | 0.2 | $5.6M | +3% | 1.4M | 4.00 |
|
An2 Therapeutics (ANTX) | 0.2 | $5.1M | -30% | 248k | 20.49 |
|
An2 Therapeutics (ANTX) | 0.2 | $5.1M | -30% | 248k | 20.49 |
|
Ideaya Biosciences (IDYA) | 0.1 | $5.0M | -4% | 139k | 35.58 |
|
Ideaya Biosciences (IDYA) | 0.1 | $5.0M | -4% | 139k | 35.58 |
|
Playags (AGS) | 0.1 | $4.8M | -4% | 567k | 8.43 |
|
Playags (AGS) | 0.1 | $4.8M | -4% | 567k | 8.43 |
|
Alteryx Com Cl A (AYX) | 0.1 | $4.7M | NEW | 99k | 47.16 |
|
Alteryx Com Cl A (AYX) | 0.1 | $4.7M | NEW | 99k | 47.16 |
|
Savara (SVRA) | 0.1 | $4.6M | -4% | 988k | 4.70 |
|
Savara (SVRA) | 0.1 | $4.6M | -4% | 988k | 4.70 |
|
Par Technology Corp Note 2.875% 4/1 (Principal) | 0.1 | $4.6M | 3.8M | 1.22 |
|
|
Par Technology Corp Note 2.875% 4/1 (Principal) | 0.1 | $4.6M | 3.8M | 1.22 |
|
|
Xtant Med Hldgs Com New (XTNT) | 0.1 | $4.5M | 4.0M | 1.13 |
|
|
Xtant Med Hldgs Com New (XTNT) | 0.1 | $4.5M | 4.0M | 1.13 |
|
|
Herman Miller (MLKN) | 0.1 | $4.5M | -50% | 167k | 26.68 |
|
Herman Miller (MLKN) | 0.1 | $4.5M | -50% | 167k | 26.68 |
|
Theratechnologies Com New (THTX) | 0.1 | $4.3M | NEW | 2.7M | 1.62 |
|
Theratechnologies Com New (THTX) | 0.1 | $4.3M | NEW | 2.7M | 1.62 |
|
Vanda Pharmaceuticals (VNDA) | 0.1 | $4.3M | 1.0M | 4.22 |
|
|
Vanda Pharmaceuticals (VNDA) | 0.1 | $4.3M | 1.0M | 4.22 |
|
|
Optinose (OPTN) | 0.1 | $4.1M | -4% | 3.1M | 1.29 |
|
Optinose (OPTN) | 0.1 | $4.1M | -4% | 3.1M | 1.29 |
|
Dariohealth Corp Com New (DRIO) | 0.1 | $4.0M | -3% | 2.3M | 1.72 |
|
Dariohealth Corp Com New (DRIO) | 0.1 | $4.0M | -3% | 2.3M | 1.72 |
|
Altisource Portfolio Solns S Reg Shs (ASPS) | 0.1 | $3.8M | +17% | 1.1M | 3.56 |
|
Altisource Portfolio Solns S Reg Shs (ASPS) | 0.1 | $3.8M | +17% | 1.1M | 3.56 |
|
Cogent Biosciences (COGT) | 0.1 | $3.8M | +11% | 641k | 5.88 |
|
Cogent Biosciences (COGT) | 0.1 | $3.8M | +11% | 641k | 5.88 |
|
Alta Equipment Group Common Stock (ALTG) | 0.1 | $3.7M | -6% | 303k | 12.37 |
|
Alta Equipment Group Common Stock (ALTG) | 0.1 | $3.7M | -6% | 303k | 12.37 |
|
Cellectar Biosciences Com New (CLRB) | 0.1 | $3.7M | NEW | 1.4M | 2.77 |
|
Cellectar Biosciences Com New (CLRB) | 0.1 | $3.7M | NEW | 1.4M | 2.77 |
|
Envveno Medical (NVNO) | 0.1 | $3.6M | NEW | 706k | 5.14 |
|
Envveno Medical (NVNO) | 0.1 | $3.6M | NEW | 706k | 5.14 |
|
Elutia Cl A Com (ELUT) | 0.1 | $3.6M | 1.7M | 2.16 |
|
|
Elutia Cl A Com (ELUT) | 0.1 | $3.6M | 1.7M | 2.16 |
|
|
StarTek | 0.1 | $3.5M | NEW | 787k | 4.41 |
|
StarTek | 0.1 | $3.5M | NEW | 787k | 4.41 |
|
Dianthus Therapeutics (DNTH) | 0.1 | $3.4M | -2% | 328k | 10.40 |
|
Dianthus Therapeutics (DNTH) | 0.1 | $3.4M | -2% | 328k | 10.40 |
|
Aytu Biopharma (AYTU) | 0.1 | $3.1M | 1.1M | 2.84 |
|
|
Aytu Biopharma (AYTU) | 0.1 | $3.1M | 1.1M | 2.84 |
|
|
Unicycive Therapeutics (UNCY) | 0.1 | $3.0M | 3.4M | 0.87 |
|
|
Unicycive Therapeutics (UNCY) | 0.1 | $3.0M | 3.4M | 0.87 |
|
|
Gaia Cl A (GAIA) | 0.1 | $2.5M | +3853% | 915k | 2.70 |
|
Gaia Cl A (GAIA) | 0.1 | $2.5M | +3853% | 915k | 2.70 |
|
Graphite Bio (GRPH) | 0.1 | $2.2M | NEW | 821k | 2.62 |
|
Graphite Bio (GRPH) | 0.1 | $2.2M | NEW | 821k | 2.62 |
|
Aerovate Therapeutics (AVTE) | 0.1 | $2.1M | -4% | 91k | 22.63 |
|
Aerovate Therapeutics (AVTE) | 0.1 | $2.1M | -4% | 91k | 22.63 |
|
Mediaalpha Cl A (MAX) | 0.1 | $2.0M | -22% | 181k | 11.15 |
|
Mediaalpha Cl A (MAX) | 0.1 | $2.0M | -22% | 181k | 11.15 |
|
Neuroone Med Technologies Com New (NMTC) | 0.1 | $1.9M | -2% | 1.2M | 1.58 |
|
Neuroone Med Technologies Com New (NMTC) | 0.1 | $1.9M | -2% | 1.2M | 1.58 |
|
Perella Weinberg Partners Class A Com (PWP) | 0.1 | $1.9M | -39% | 156k | 12.23 |
|
Perella Weinberg Partners Class A Com (PWP) | 0.1 | $1.9M | -39% | 156k | 12.23 |
|
Jasper Therapeutics | 0.1 | $1.8M | -7% | 2.2M | 0.79 |
|
Strata Skin Sciences Com New (SSKN) | 0.1 | $1.7M | -4% | 3.1M | 0.55 |
|
Strata Skin Sciences Com New (SSKN) | 0.1 | $1.7M | -4% | 3.1M | 0.55 |
|
Immatics *w Exp 07/01/202 (IMTXW) | 0.0 | $1.6M | 559k | 2.92 |
|
|
Immatics *w Exp 07/01/202 (IMTXW) | 0.0 | $1.6M | 559k | 2.92 |
|
|
Conn's (CONN) | 0.0 | $1.6M | NEW | 359k | 4.44 |
|
Conn's (CONN) | 0.0 | $1.6M | NEW | 359k | 4.44 |
|
Selecta Biosciences (RNAC) | 0.0 | $1.5M | 2.2M | 0.69 |
|
|
Selecta Biosciences (RNAC) | 0.0 | $1.5M | 2.2M | 0.69 |
|
|
Rezolute Com New (RZLT) | 0.0 | $1.5M | +99% | 1.5M | 0.99 |
|
Rezolute Com New (RZLT) | 0.0 | $1.5M | +99% | 1.5M | 0.99 |
|
Scully Royalty Com Shs (SRL) | 0.0 | $1.5M | -18% | 243k | 6.10 |
|
Scully Royalty Com Shs (SRL) | 0.0 | $1.5M | -18% | 243k | 6.10 |
|
Acelrx Pharmaceuticals Com New (ACRX) | 0.0 | $1.5M | +3% | 2.0M | 0.73 |
|
Acelrx Pharmaceuticals Com New (ACRX) | 0.0 | $1.5M | +3% | 2.0M | 0.73 |
|
Neurogene | 0.0 | $1.4M | NEW | 72k | 19.38 |
|
Neurogene | 0.0 | $1.4M | NEW | 72k | 19.38 |
|
B. Riley Financial (RILY) | 0.0 | $1.3M | 63k | 20.99 |
|
|
B. Riley Financial (RILY) | 0.0 | $1.3M | 63k | 20.99 |
|
|
Zynex (ZYXI) | 0.0 | $1.3M | NEW | 120k | 10.89 |
|
Zynex (ZYXI) | 0.0 | $1.3M | NEW | 120k | 10.89 |
|
Eargo Com New (EAR) | 0.0 | $1.3M | NEW | 496k | 2.59 |
|
Eargo Com New (EAR) | 0.0 | $1.3M | NEW | 496k | 2.59 |
|
Anebulo Pharmaceuticals (ANEB) | 0.0 | $1.2M | 511k | 2.42 |
|
|
Anebulo Pharmaceuticals (ANEB) | 0.0 | $1.2M | 511k | 2.42 |
|
|
Cidara Therapeutics Inc Common Stock Usd 0.0001 (CDTX) | 0.0 | $1.2M | -39% | 1.5M | 0.79 |
|
Cidara Therapeutics Inc Common Stock Usd 0.0001 (CDTX) | 0.0 | $1.2M | -39% | 1.5M | 0.79 |
|
Fortress Biotech Com New (FBIO) | 0.0 | $1.1M | NEW | 373k | 3.01 |
|
Fortress Biotech Com New (FBIO) | 0.0 | $1.1M | NEW | 373k | 3.01 |
|
Instil Bio Com New | 0.0 | $970k | NEW | 127k | 7.62 |
|
Instil Bio Com New | 0.0 | $970k | NEW | 127k | 7.62 |
|
Spar (SGRP) | 0.0 | $888k | 879k | 1.01 |
|
|
Spar (SGRP) | 0.0 | $888k | 879k | 1.01 |
|
|
Cutera Note 4.000% 6/0 (Principal) | 0.0 | $876k | NEW | 4.0M | 0.22 |
|
Cutera Note 4.000% 6/0 (Principal) | 0.0 | $876k | NEW | 4.0M | 0.22 |
|
Gossamer Bio (GOSS) | 0.0 | $614k | -88% | 673k | 0.91 |
|
Gossamer Bio (GOSS) | 0.0 | $614k | -88% | 673k | 0.91 |
|
Fossil (FOSL) | 0.0 | $592k | -58% | 405k | 1.46 |
|
Fossil (FOSL) | 0.0 | $592k | -58% | 405k | 1.46 |
|
Recro Pharma (SCTL) | 0.0 | $426k | -2% | 1.2M | 0.35 |
|
Recro Pharma (SCTL) | 0.0 | $426k | -2% | 1.2M | 0.35 |
|
Sensus Healthcare (SRTS) | 0.0 | $417k | -4% | 177k | 2.36 |
|
Sensus Healthcare (SRTS) | 0.0 | $417k | -4% | 177k | 2.36 |
|
Gamida Cell SHS (GMDA) | 0.0 | $330k | -81% | 800k | 0.41 |
|
Gamida Cell SHS (GMDA) | 0.0 | $330k | -81% | 800k | 0.41 |
|
Aptose Biosciences (APTO) | 0.0 | $305k | -11% | 120k | 2.54 |
|
Aptose Biosciences (APTO) | 0.0 | $305k | -11% | 120k | 2.54 |
|
Ladder Cap Corp Cl A (LADR) | 0.0 | $295k | -5% | 26k | 11.51 |
|
Ladder Cap Corp Cl A (LADR) | 0.0 | $295k | -5% | 26k | 11.51 |
|
Lucid Diagnostics (LUCD) | 0.0 | $211k | -5% | 150k | 1.41 |
|
Lucid Diagnostics (LUCD) | 0.0 | $211k | -5% | 150k | 1.41 |
|
TransAct Technologies Incorporated (TACT) | 0.0 | $196k | -9% | 28k | 6.98 |
|
TransAct Technologies Incorporated (TACT) | 0.0 | $196k | -9% | 28k | 6.98 |
|
Exagen (XGN) | 0.0 | $193k | -9% | 97k | 1.99 |
|
Exagen (XGN) | 0.0 | $193k | -9% | 97k | 1.99 |
|
Bm Technologies Cl A Com (BMTX) | 0.0 | $156k | -4% | 76k | 2.05 |
|
Bm Technologies Cl A Com (BMTX) | 0.0 | $156k | -4% | 76k | 2.05 |
|
Rafael Hldgs Com Cl B (RFL) | 0.0 | $133k | 73k | 1.83 |
|
|
Rafael Hldgs Com Cl B (RFL) | 0.0 | $133k | 73k | 1.83 |
|
|
Cue Biopharma (CUE) | 0.0 | $71k | 27k | 2.64 |
|
|
Cue Biopharma (CUE) | 0.0 | $71k | 27k | 2.64 |
|
|
Check Cap SHS (CHEK) | 0.0 | $70k | NEW | 33k | 2.08 |
|
Check Cap SHS (CHEK) | 0.0 | $70k | NEW | 33k | 2.08 |
|
Guardforce Ai *w Exp 10/01/202 (GFAIW) | 0.0 | $26k | 154k | 0.17 |
|
|
Guardforce Ai *w Exp 10/01/202 (GFAIW) | 0.0 | $26k | 154k | 0.17 |
|
|
Tc Biopharm Holdings *w Exp 02/10/202 (TCBPW) | 0.0 | $7.6k | 235k | 0.03 |
|
|
Tc Biopharm Holdings *w Exp 02/10/202 (TCBPW) | 0.0 | $7.6k | 235k | 0.03 |
|
|
Kintara Therapeutics Com New (KTRA) | 0.0 | $3.7k | -2% | 22k | 0.17 |
|
Kintara Therapeutics Com New (KTRA) | 0.0 | $3.7k | -2% | 22k | 0.17 |
|
Past Filings by Nantahala Capital Management
SEC 13F filings are viewable for Nantahala Capital Management going back to 2011
- Nantahala Capital Management 2023 Q4 amended filed Feb. 15, 2024
- Nantahala Capital Management 2023 Q4 filed Feb. 14, 2024
- Nantahala Capital Management 2023 Q3 filed Nov. 14, 2023
- Nantahala Capital Management 2023 Q2 filed Aug. 14, 2023
- Nantahala Capital Management 2023 Q1 filed May 15, 2023
- Nantahala Capital Management 2022 Q4 filed Feb. 14, 2023
- Nantahala Capital Management 2022 Q3 filed Nov. 10, 2022
- Nantahala Capital Management 2022 Q2 filed Aug. 15, 2022
- Nantahala Capital Management 2022 Q1 filed May 13, 2022
- Nantahala Capital Management 2021 Q4 filed Feb. 14, 2022
- Nantahala Capital Management 2021 Q3 filed Nov. 15, 2021
- Nantahala Capital Management 2021 Q2 filed Aug. 16, 2021
- Nantahala Capital Management 2021 Q1 filed May 14, 2021
- Nantahala Capital Management 2020 Q4 filed Feb. 16, 2021
- Nantahala Capital Management 2020 Q3 filed Nov. 16, 2020
- Nantahala Capital Management 2020 Q2 filed Aug. 14, 2020